ACME Laboratories (DHA:ACMELAB) Total Current Liabilities: BDT21,887 Mil (As of Mar. 2026)


DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
90 GF Score
Price BDT84.50
GF Value BDT125.40
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is ACME Laboratories Total Current Liabilities?

ACME Laboratories DHA:ACMELAB +1.08% 90 Total Current Liabilities is BDT21,887 Mil as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 90/100 and a GF Value™ of BDT125.40 (Possible Value Trap). The stock has 7 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. ACME Laboratories's total current liabilities for the quarter that ended in Mar. 2026 was BDT21,887


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


ACME Laboratories Total Current Liabilities Related Terms


ACME Laboratories Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories Total Current Liabilities Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only 13,981.80 13,487.13 15,437.67 18,953.41 21,530.92

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23,610.88 24,033.77 21,660.00 22,998.14 21,886.90
DHA:ACMELAB
90GF Score
ACME Laboratories Ltd DHA:ACMELAB
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACME Laboratories Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

ACME Laboratories's Total Current Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=965.181+17189.502
+Other Current Liabilities+Current Deferred Liabilities
=3376.239+0
=21,531

ACME Laboratories's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=532.683+16656.442
+Other Current Liabilities+Current Deferred Liabilities
=4697.774+0
=21,887

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of BDT21,887 Mil mean?
ACME Laboratories (DHA:ACMELAB) has a Total Current Liabilities of BDT21,887 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for ACME Laboratories and its competitors.
Is ACME Laboratories' Total Current Liabilities too high?
ACME Laboratories' current Total Current Liabilities is BDT21,887 Mil. Overall, ACME Laboratories has a GF Score™ of 90/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Total Current Liabilities compare to ZTS and UTHR?
ACME Laboratories' Total Current Liabilities of BDT21,887 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for ACME Laboratories and its competitors. ACME Laboratories's current Total Current Liabilities is BDT21,887 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.40, compared to a current price of BDT84.50 — trading 32.6% below its estimated fair value. The current Total Current Liabilities is BDT21,887 Mil. ACME Laboratories' overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Total Current Liabilities is BDT21,887 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT84.50 is trading 32.6% below its estimated GF Value™ of BDT125.40. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • Total Current Liabilities: BDT21,887 Mil
  • GF Value™: BDT125.40 vs. price of BDT84.50 (32.6% below fair value)
  • GF Score™: 90/100 with 7 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
90GF Score

Get the complete analysis for DHA:ACMELAB

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT84.50
Price
BDT125.40
GF Value